Emselex darifenacin regulatory update

EC granted marketing authorization to Emselex 7.5 and 15 mg formulations to treat overactive bladder (OAB). The M3-selective receptor antagonist was acquired from Pfizer Inc. (PFE, New York, N.Y.) in...